Cardiovascular risk of adipokines
What is it about?
Over the last two decades, the understanding of adipose tissue has undergone radical change. The perception has evolved from an inert energy storage tissue, to that of an active endocrine organ. Adipose tissue releases a cluster of active molecules, currently named adipokines. The severity of obesity-related diseases does not necessarily correlate with the extent of body fat accumulation, but is closely related to body fat distribution, particularly to visceral localization. There is a distinction between the the metabolic function of central obesity (visceral abdominal) and peripheral obesity (subcutaneous) in the production of adipokines. Visceral fat accumulation, linked with the levels of some adipokines induces chronic inflammation and metabolic disorders, including glucose intolerance, hyperlipidemia, and arterial hypertension. Together, these conditions contribute to a diagnosis of metabolic syndrome, directly associated with the onset of cardiovascular disease. If it is well known that adipokines contribute to inflammatory profile and appetite regulation, this review is novel in synthesising the current state of knowledge of the role of visceral adipose tissue and its secretion of adipokines on cardiovascular risk.
Why is it important?
This review is novel in synthesising the current state of knowledge of the role of visceral adipose tissue and its secretion of adipokines on cardiovascular risk.
The following have contributed to this page: Professor Fred Dutheil
In partnership with: